About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
BLUE - bluebird bio| Previous Close | $28.12 | Open | $28.24 |
| Volume | 5.9M | Market Cap | 1.866B |
| Yield | Last Dividend |
| Breaking Notice: Rosen, a Globally Recog... | 2:01 PM |
| WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of bluebird bio, Inc. between May 11, 2020 and November 4... | |
| Breaking Notice: Rosen, a Globally Recog... | 2:00 PM |
| WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of bluebird bio, Inc. (NASDAQ:BLUE) between May 11, 2020 ... | |
| bluebird bio to Present at Cowen Health ... | 02/26/21 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the Cowen... | |
| RBC Capital Stick to Their Hold Rating f... | 02/25/21 |
| RBC Capital Stick to Their Hold Rating for bluebird bio | |
| The New England Journal of Medicine Publ... | 02/24/21 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Results from the pivotal Phase 2 KarMMa study evaluating the efficacy and safety of bluebird bio, Inc. (Nasdaq: BLU... | |
| Gene therapy leaders may need M&A to sol... | 02/24/21 |
| Summary List Placement Reports of patients deaths, cancer cases, and other potential safety issues in the gene therapy field have made some investors ... | |
| Glancy Prongay & Murray LLP Reminds Inve... | 02/24/21 |
| LOS ANGELES--(BUSINESS WIRE)---- $BLUE #CLASSACTION--Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Aga... | |
| BLUE Shareholder Alert: Bronstein, Gewir... | 02/24/21 |
| NEW YORK--(BUSINESS WIRE)--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against bluebird bio, Inc.... | |
| The Daily Biotech Pulse: Bausch Calls Tr... | 02/24/21 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 23) Axo... | |
| bluebird bio Reports Fourth Quarter and ... | 02/23/21 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ:BLUE) today reported financial results and business highlights for the fourth quarter an... | |
| The Daily Biotech Pulse: Aridis To Study... | 02/23/21 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 22) Acc... | |
| bluebird bio to Present at Leerink Globa... | 02/22/21 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the 10th ... | |
| Glancy Prongay & Murray LLP, a Leading S... | 02/22/21 |
| LOS ANGELES--(BUSINESS WIRE)---- $BLUE #CLASSACTION--Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Secur... | |
| Insider Selling: bluebird bio, Inc. (NAS... | 02/21/21 |
| bluebird bio, Inc. (NASDAQ:BLUE) CFO William D. Baird III sold 693 shares of bluebird bio stock in a transaction on Wednesday, February 17th. The stoc... | |
| The Week Ahead In Biotech: J&J Vaccine A... | 02/20/21 |
| Biotech stocks pulled back along with the broader market in the holiday-shortened week ended Feb 19. Earnings news flow was light before picking up pa... | |
| Bluebird Bio Inc Has Returned 40.5% Sinc... | 02/19/21 |
| Feb 19, 2021 (SmarTrend(R) Spotlight via COMTEX) -- SmarTrend identified a Downtrend for Bluebird Bio Inc (NASDAQ:BLUE) on January 29th, 2021 at $45.0... | |
| The Law Offices of Frank R. Cruz Announc... | 02/19/21 |
| LOS ANGELES--(BUSINESS WIRE)---- $BLUE #investors--The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of blu... | |
| BLUE Stock: Berger Montague Investigates... | 02/19/21 |
| PHILADELPHIA, Feb. 19, 2021 /PRNewswire/ -- Berger Montague is investigating potential securities fraud claims against bluebird bio, Inc. ("bluebird" ... | |
| Barclays Stick to Their Hold Rating for ... | 02/18/21 |
| Barclays Stick to Their Hold Rating for bluebird bio | |
| Listen: Gene therapy's safety scare & bi... | 02/18/21 |
| We break down a significant setback for Bluebird Bio???s gene therapy program with some help from bone marrow transplant expert Akshay Sharma. | |
| INVESTOR ACTION ALERT: The Schall Law Fi... | 02/18/21 |
| Los Angeles, CA - (NewMediaWire) - February 18, 2021 - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a c... | |
| Glancy Prongay & Murray LLP, a Leading S... | 02/18/21 |
| LOS ANGELES--(BUSINESS WIRE)---- $BLUE #CLASSACTION--Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of blue... | |
| BLUE INVESTOR ALERT: Bernstein Liebhard ... | 02/17/21 |
| NEW YORK, Feb. 17, 2021 /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, announces that a securities class action ... | |
| BREAKING ALERT: ROSEN, GLOBAL INVESTOR C... | 02/17/21 |
| NEW YORK , Feb. 17, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on beh... | |
| The Law Offices of Frank R. Cruz Announc... | 02/17/21 |
| LOS ANGELES--(BUSINESS WIRE)---- $BLUE #investors--The Law Offices of Frank R. Cruz Announces Investigation of bluebird bio, Inc. (BLUE) on Behalf of ... | |
| Shareholder Alert: Robbins LLP Announces... | 02/17/21 |
| SAN DIEGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BLUE #ClassAction--Shareholder rights law firm Robbins LLP announces that a purchaser of bluebird b... | |
| Top Analyst Upgrades and Downgrades: Agi... | 02/17/21 |
| No summary available. | |
| STAT+: Cancer cases place Bluebird Bio??... | 02/17/21 |
| Cancer cases place Bluebird Bio's gene therapy business at a crossroads, and might drag the entire field along. | |
| Bluebird Bio Temporarily Suspends Sickle... | 02/16/21 |
| Shares of bluebird bio Inc (NASDAQ: BLUE ) were sinking Tuesday morning following an adverse clinical pipeline development. What Happened: Cambridge, ... | |
| BLUE Investor Alert: Bronstein, Gewirtz ... | 02/16/21 |
| NEW YORK, Feb. 16, 2021 /PRNewswire/ -- Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has b... | |
| Hold rating | 02/17/21 |
| JP Morgan downgrades from Overweight to Neutral rating and lowers Price Target from $76.00 to $39.00 | |
| Date | 2021-02-23 (BMO) | Est. (EPS/Rev.) | ($2.92)/ 14.65M |
| Actual (EPS/Rev.) | $-3.01/ $10.71 M | EPS (TTM) | 0 |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| Swingtrades | R. belegger | 83.00 % | Follow |
| Stocks and Options Elite | Calvin Moore | 75.00 % | Subscribe |
| Analyst Rating Investments | BigMoveTrader | 69.00 % | Follow |
| Lewis Aung's long pick | Kyaw Aung | 69.00 % | Subscribe |
| LavaPit | Steve Pitkin | 57.00 % | Follow |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
